{
    "organizations": [],
    "uuid": "88fe73b7600a33720b85f83e7d97526b3f495a4b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-moodys-says-87-bln-acquisition-of/brief-moodys-says-8-7-bln-acquisition-of-avexis-strengthens-novartiss-pipeline-in-gene-therapy-idUSFWN1RN0B8",
    "ord_in_thread": 0,
    "title": "BRIEF-Moody's Says $8.7 bln Acquisition Of Avexis Strengthens Novartis's Pipeline In Gene Therapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10, 2018 / 8:27 AM / Updated 12 minutes ago BRIEF-Moody's Says $8.7 bln Acquisition Of Avexis Strengthens Novartis's Pipeline In Gene Therapy Reuters Staff 1 Min Read \n  Moody’s: \n* MOODY’S SAYS $8.7 BILLION ACQUISITION OF AVEXIS STRENGTHENS NOVARTIS’S PIPELINE IN GENE THERAPY, BUT REDUCES FINANCIAL FLEXIBILITY \n* MOODY’S SAYS MONETISING VALUE OF JV STAKE HAS REDUCED DIVERSITY BUT INCREASED CASH BALANCES, AND LEFT UNCERTAINTY OVER USE OF PROCEEDS \n* MOODY’S SAYS EXPECT THAT AVXS-101, IF APPROVED, WILL ONLY HAVE A MEANINGFUL IMPACT ON NOVARTIS’S EBITDA AND CREDIT METRICS FROM 2020 ONWARDS \n* MOODY'S SAYS DEAL WILL NOT DO MUCH TO IMPROVE NOVARTIS'S CREDIT METRICS OVER NEXT 2 YEARS AND WE EXPECT COMPANY TO CONTINUE OPERATING WITH A LEVERAGE Source: bit.ly/2HegzGl Further company coverage:",
    "published": "2018-04-10T11:24:00.000+03:00",
    "crawled": "2018-04-10T11:38:52.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "say",
        "bln",
        "acquisition",
        "avexis",
        "strengthens",
        "novartis",
        "pipeline",
        "gene",
        "therapy",
        "reuters",
        "staff",
        "min",
        "read",
        "moody",
        "moody",
        "say",
        "billion",
        "acquisition",
        "avexis",
        "strengthens",
        "novartis",
        "pipeline",
        "gene",
        "therapy",
        "reduces",
        "financial",
        "flexibility",
        "moody",
        "say",
        "monetising",
        "value",
        "jv",
        "stake",
        "reduced",
        "diversity",
        "increased",
        "cash",
        "balance",
        "left",
        "uncertainty",
        "use",
        "proceeds",
        "moody",
        "say",
        "expect",
        "approved",
        "meaningful",
        "impact",
        "novartis",
        "ebitda",
        "credit",
        "metric",
        "onwards",
        "moody",
        "say",
        "deal",
        "much",
        "improve",
        "novartis",
        "credit",
        "metric",
        "next",
        "year",
        "expect",
        "company",
        "continue",
        "operating",
        "leverage",
        "source",
        "company",
        "coverage"
    ]
}